Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, B-Cell, Marginal Zone 4Waldenstrom Macroglobulinemia 3Leukemia 3Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Leukemia, B-Cell 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Rituximab 77Cyclophosphamide 54fludarabine phosphate 50Peripheral Blood Stem Cell Transplantation 44Mycophenolic Acid 34Whole-Body Irradiation 33Tacrolimus 25Cyclosporine 23Busulfan 22Bortezomib 22Dexamethasone 21Etoposide 19ibrutinib 18Melphalan 17Antilymphocyte Serum 17Methotrexate 15Lenalidomide 15Filgrastim 14Radiotherapy 12Bendamustine Hydrochloride 12Sirolimus 10Calcium Dobesilate 10Flow Cytometry 9Everolimus 9Cyclosporins 9zanubrutinib 8Alemtuzumab 7ibritumomab tiuxetan 6Transplantation 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Waldenstrom Macroglobulinemia × pirtobrutinib × Clear all
NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05734495 2026-05-28

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
46 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07548450 2026-04-23

MPOWER

University of Utah

Phase 2 Not yet recruiting
25 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡